Other
Leigh Syndrome
5
Pipeline Programs↗
2
Active Trials↗
4
Companies Involved↗
Leigh syndrome is an early-stage landscape with 5 programs across 4 companies. The most active players are Thiogenesis Therapeutics, Inc., PTC Therapeutics, Prism Pharmaceuticals.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 25
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
4
clinical trials
Completed2 · 50%
Enrolling by invitation1 · 25%
Not yet recruiting1 · 25%
Clinical Trials
Trial Activity
Sirolimus for Leigh Syndrome
Enrolling by invitation·—·Phase 2·NCT06843811·15 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)